{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:13:34Z","timestamp":1792293214267,"version":"4.4.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Local immunotherapy induced systemic responses in patients with disseminated FL. Clinical responses correlated with systemic antitumor T-cell immunity.<\/jats:p>","DOI":"10.1182\/blood-2014-07-592162","type":"journal-article","created":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T01:04:47Z","timestamp":1412730287000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma"],"prefix":"10.1182","volume":"125","author":[{"given":"Arne","family":"Kolstad","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway;"},{"name":"K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Kumari","sequence":"additional","affiliation":[{"name":"K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"},{"name":"Department of Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Walczak","sequence":"additional","affiliation":[{"name":"K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"},{"name":"Department of Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Madsbu","sequence":"additional","affiliation":[{"name":"Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Hagtvedt","sequence":"additional","affiliation":[{"name":"Department of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond Velde","family":"Bogsrud","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kvalheim","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapies, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Holte","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Aurlien","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Delabie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oslo University Hospital Radiumhospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Olweus","sequence":"additional","affiliation":[{"name":"K. G. Jebsen Center for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway;"},{"name":"Department of Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2019111822164402800_B1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma.","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2019111822164402800_B2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111822164402800_B3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111822164402800_B4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111822164402800_B5","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"issue":"19","key":"2019111822164402800_B6","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","article-title":"Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin\u2019s lymphoma resulting in durable clinical responses.","volume":"24","author":"Redfern","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111822164402800_B7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","article-title":"Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.","volume":"98","author":"Inog\u00e8s","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 4","key":"2019111822164402800_B8","first-page":"iv101","article-title":"Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (FNHL).","volume":"19","author":"Levy","year":"2008","journal-title":"Ann Oncol"},{"issue":"18","key":"2019111822164402800_B9","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111822164402800_B10","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111822164402800_B11","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2010.33.4623","article-title":"Active and passive immunotherapy for lymphoma: proving principles and improving results.","volume":"29","author":"Brody","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111822164402800_B12","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"issue":"5","key":"2019111822164402800_B13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2010-06-292342","article-title":"Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.","volume":"117","author":"Navarrete","year":"2011","journal-title":"Blood"},{"issue":"33","key":"2019111822164402800_B14","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma.","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111822164402800_B15","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.","volume":"21","author":"Haas","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111822164402800_B16","doi-asserted-by":"crossref","first-page":"e26536","DOI":"10.4161\/onci.26536","article-title":"Immunogenic cell death in radiation therapy.","volume":"2","author":"Galluzzi","year":"2013","journal-title":"OncoImmunology"},{"issue":"3","key":"2019111822164402800_B17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership.","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2019111822164402800_B18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ijc.20036","article-title":"Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity.","volume":"109","author":"Kim","year":"2004","journal-title":"Int J Cancer"},{"issue":"6","key":"2019111822164402800_B19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri2780","article-title":"Cross-priming in health and disease.","volume":"10","author":"Kurts","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2019111822164402800_B20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20011097","article-title":"Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.","volume":"195","author":"Dhodapkar","year":"2002","journal-title":"J Exp Med"},{"key":"2019111822164402800_B21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2407-7-119","article-title":"A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines.","volume":"7","author":"Jarnjak-Jankovic","year":"2007","journal-title":"BMC Cancer"},{"issue":"1-2","key":"2019111822164402800_B22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"issue":"1","key":"2019111822164402800_B23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1073\/pnas.1306549111","article-title":"Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.","volume":"111","author":"Kumari","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111822164402800_B24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111822164402800_B25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"282","key":"2019111822164402800_B26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2019111822164402800_B27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cncr.22389","article-title":"Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"2019111822164402800_B28","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111822164402800_B29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","article-title":"Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.","volume":"113","author":"Di Nicola","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111822164402800_B30","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2006-12-063594","article-title":"A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma.","volume":"109","author":"Neelapu","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111822164402800_B31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2006.03.007","article-title":"Enhanced antitumor effect of dendritic cell based immunotherapy after intratumoral injection of radionuclide Ho-166 against B16 melanoma.","volume":"106","author":"Lee","year":"2006","journal-title":"Immunol Lett"},{"issue":"8","key":"2019111822164402800_B32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/CJI.0b013e31826f79a6","article-title":"Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.","volume":"35","author":"Son","year":"2012","journal-title":"J Immunother"},{"issue":"12","key":"2019111822164402800_B33","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1097-0142(20001215)89:12<2646::AID-CNCR18>3.0.CO;2-A","article-title":"Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer.","volume":"89","author":"Triozzi","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"2019111822164402800_B34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.cji.0000154248.74383.5e","article-title":"Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.","volume":"28","author":"Chi","year":"2005","journal-title":"J Immunother"},{"issue":"28","key":"2019111822164402800_B35","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study.","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111822164402800_B36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study.","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111822164402800_B37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"suppl 1","key":"2019111822164402800_B38","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/eji.200737400","article-title":"Dendritic cells: understanding immunogenicity.","volume":"37","author":"Steinman","year":"2007","journal-title":"Eur J Immunol"},{"issue":"14","key":"2019111822164402800_B39","first-page":"5091","article-title":"Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.","volume":"9","author":"de Vries","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019111822164402800_B40","first-page":"4035","article-title":"Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.","volume":"59","author":"Nishioka","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"2019111822164402800_B41","first-page":"2209","article-title":"CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes.","volume":"60","author":"Hirao","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"2019111822164402800_B42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/10428190802617805","article-title":"Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.","volume":"50","author":"Peinert","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111822164402800_B43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action.","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"12","key":"2019111822164402800_B44","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.20020338","article-title":"Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.","volume":"195","author":"Kalergis","year":"2002","journal-title":"J Exp Med"},{"issue":"2","key":"2019111822164402800_B45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1269\/jrr.47.183","article-title":"Rituximab enhances radiation-triggered apoptosis in non-Hodgkin\u2019s lymphoma cells via caspase-dependent and -independent mechanisms.","volume":"47","author":"Skvortsova","year":"2006","journal-title":"J Radiat Res (Tokyo)"},{"issue":"3","key":"2019111822164402800_B46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2133.2005.06433.x","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.","volume":"152","author":"Roguedas","year":"2005","journal-title":"Br J Dermatol"},{"issue":"6","key":"2019111822164402800_B47","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"issue":"6","key":"2019111822164402800_B48","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188.2188_2188_2195","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/1\/82\/1383774\/82.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/1\/82\/1383774\/82.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:17:05Z","timestamp":1574115425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/1\/82\/33936\/Sequential-intranodal-immunotherapy-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-07-592162","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,1]]}}}